Chemomab Therapeutics Ltd.
CMMB Nasdaq
SEC CIK 1534248
Follow Chemomab Therapeutics Ltd.
Weekly email: filings, results, news
EPS, diluted
-
Source: SEC XBRL filings · latest filing
Show the numbers
| Year | Net income |
|---|---|
| FY25 | −$9M |
| FY24 | −$13.9M |
| FY23 | −$24.2M |
| FY22 | −$27.6M |
| FY21 | −$12.5M |
| FY20 | −$6M |
| FY19 | −$27.1M |
| FY18 | −$13.8M |
| FY17 | - |
Show the numbers
| Year | Free cash flow |
|---|---|
| FY25 | −$11.1M |
| FY24 | −$15.4M |
| FY23 | −$23.6M |
| FY22 | −$20.4M |
| FY21 | −$12.6M |
| FY20 | −$5.3M |
| FY19 | −$16.6M |
| FY18 | −$14.4M |
| FY17 | - |
News
No stories filed under Chemomab Therapeutics Ltd. yet - coverage appears here as the news feed clusters it.